AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
197.69
+0.31 (0.16%)
At close: Apr 28, 2026, 4:00 PM EDT
197.99
+0.30 (0.15%)
After-hours: Apr 28, 2026, 7:59 PM EDT
AbbVie Revenue
In the year 2025, AbbVie had annual revenue of $61.16B with 8.57% growth. AbbVie had revenue of $16.62B in the quarter ending December 31, 2025, with 10.04% growth.
Revenue (ttm)
$61.16B
Revenue Growth
+8.57%
P/S Ratio
5.72
Revenue / Employee
$1,072,982
Employees
57,000
Market Cap
349.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 61.16B | 4.83B | 8.57% |
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Eli Lilly and Company | 65.18B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.58B |
| Sanofi | 54.60B |
| Novo Nordisk | 48.59B |
ABBV News
- 15 hours ago - AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata - PRNewsWire
- 16 hours ago - EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie - GlobeNewsWire
- 1 day ago - AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease - PRNewsWire
- 5 days ago - US FDA declines to approve AbbVie's wrinkle treatment - Reuters
- 5 days ago - AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S. - PRNewsWire
- 6 days ago - AbbVie to build $1.4 billion manufacturing campus in North Carolina - Reuters
- 6 days ago - AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus - PRNewsWire
- 8 days ago - Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases - GlobeNewsWire